PRDX2

Summary

PRDX2 (peroxiredoxin 2, HGNC:9353) is a protein-coding gene on chromosome 19p13.13, encoding Peroxiredoxin-2 (P32119). Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively.

This gene encodes a member of the peroxiredoxin family of antioxidant enzymes, which reduce hydrogen peroxide and alkyl hydroperoxides. The encoded protein plays an antioxidant protective role in cells, and it may contribute to the antiviral activity of CD8(+) T-cells. The crystal structure of this protein has been resolved to 2.7 angstroms. This protein prevents hemolytic anemia from oxidative stress by stabilizing hemoglobin, thus making this gene a therapeutic target for patients with hemolytic anemia. This protein may have a proliferative effect and play a role in cancer development or progression. Related pseudogenes have been identified on chromosomes 5, 6, 10 and 13.

Source: NCBI Gene 7001 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 20 total
• GTEx eGene: eQTL in 26 tissues, sQTL in 2 (q < 0.05)
• Constraint (gnomAD): pLI 0.04 (LoF-tolerant), LOEUF 0.85 (unconstrained)
• MANE Select transcript: NM_005809

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9353
Approved symbol	PRDX2
Name	peroxiredoxin 2
Location	19p13.13
Locus type	gene with protein product
Status	Approved
Aliases	PRP, NKEFB, TSA, PRXII, PRX2, MGC4104
Ensembl gene	ENSG00000167815
Ensembl biotype	protein_coding
OMIM	600538
Entrez	7001

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 16 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay

MANE Select: ENST00000301522

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 3, TSL 3: 1

ENST00000301522, ENST00000334482, ENST00000466174, ENST00000477555, ENST00000478908, ENST00000498785, ENST00000866178, ENST00000866180, ENST00000866181, ENST00000955165, ENST00000992591, ENST00001013549, ENST00001013550, ENST00001058160, ENST00001058164, ENST00001100813, ENST00001100814, ENST00001100815, ENST00001100816, ENST00001100817, ENST00001100818, ENST00001140878

RefSeq mRNA: 1 — MANE Select: NM_005809 NM_005809

CCDS: CCDS12281

Canonical transcript exons

ENST00000301522 — 6 exons

Exon	Start	End
ENSE00001117400	12800177	12800299
ENSE00001718527	12799859	12799989
ENSE00001899489	12801740	12801800
ENSE00003533436	12801159	12801270
ENSE00003574969	12800916	12801069
ENSE00003644940	12796823	12797166

Expression profiles

Bgee: expression breadth ubiquitous, 304 present calls, max score 99.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 192.8225 / max 5871.7591, expressed in 1800 samples.

Highest expression (Bgee): lateral nuclear group of thalamus, substantia nigra pars compacta, trabecular bone tissue, substantia nigra pars reticulata, lateral globus pallidus.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PRDX2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 26 tissues and its splicing (sQTL) in 2 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 28 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Artery Tibial	eqtl	1.2e-28	+0.20	19:12766150:G:C
Artery Aorta	eqtl	4.1e-24	+0.29	19:12766150:G:C
Cells Cultured fibroblasts	eqtl	6.1e-21	-0.24	19:12828978:T:C
Nerve Tibial	eqtl	1.1e-17	-0.18	19:12811689:A:G
Whole Blood	eqtl	2.5e-15	+0.14	19:12766150:G:C
Cells EBV-transformed lymphocytes	eqtl	4.6e-15	+0.59	19:12766150:G:C
Skin Sun Exposed Lower leg	eqtl	2.9e-14	+0.13	19:12766150:G:C
Lung	eqtl	7.4e-14	+0.19	19:12766150:G:C
Spleen	eqtl	2.9e-12	+0.34	19:12766150:G:C
Esophagus Mucosa	eqtl	1.8e-10	-0.15	19:12828978:T:C
Thyroid	eqtl	1.0e-09	+0.10	19:12766150:G:C
Muscle Skeletal	eqtl	1.2e-08	-0.09	19:12811689:A:G
Adipose Subcutaneous	eqtl	2.6e-08	-0.13	19:12811689:A:G
Esophagus Muscularis	eqtl	6.0e-08	-0.11	19:12828978:T:C
Colon Transverse	eqtl	8.9e-08	+0.13	19:12766150:G:C
Colon Sigmoid	eqtl	3.4e-07	+0.15	19:12766150:G:C
Stomach	eqtl	2.0e-05	+0.15	19:12766150:G:C
Skin Not Sun Exposed Suprapubic	eqtl	6.2e-05	+0.11	19:12766150:G:C
Artery Coronary	eqtl	3.5e-04	+0.18	19:12766150:G:C
Small Intestine Terminal Ileum	eqtl	4.4e-04	+0.14	19:12685621:T:C

FANTOM5 promoters

6 alternative TSS:

Promoter ID	TPM avg	Samples expressed
179391	123.5253	1789
179393	29.9508	1738
179392	29.1224	1726
179394	9.1503	1630
179390	0.8358	402
179389	0.2380	100

Top tissues by expression

showing 100 of 304 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	99.86	gold quality
substantia nigra pars compacta	UBERON:0001965	99.84	gold quality
trabecular bone tissue	UBERON:0002483	99.84	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.81	gold quality
lateral globus pallidus	UBERON:0002476	99.71	gold quality
pons	UBERON:0000988	99.70	gold quality
heart right ventricle	UBERON:0002080	99.65	gold quality
apex of heart	UBERON:0002098	99.64	gold quality
right adrenal gland cortex	UBERON:0035827	99.64	gold quality
right adrenal gland	UBERON:0001233	99.63	gold quality
left adrenal gland	UBERON:0001234	99.59	gold quality
adrenal cortex	UBERON:0001235	99.58	gold quality
left adrenal gland cortex	UBERON:0035825	99.57	gold quality
superior vestibular nucleus	UBERON:0007227	99.54	gold quality
embryo	UBERON:0000922	99.49	gold quality
adrenal gland	UBERON:0002369	99.48	gold quality
prefrontal cortex	UBERON:0000451	99.47	gold quality
cardiac ventricle	UBERON:0002082	99.47	gold quality
heart left ventricle	UBERON:0002084	99.47	gold quality
ganglionic eminence	UBERON:0004023	99.45	gold quality
right frontal lobe	UBERON:0002810	99.44	gold quality
right atrium auricular region	UBERON:0006631	99.44	gold quality
Brodmann (1909) area 10	UBERON:0013541	99.43	gold quality
penis	UBERON:0000989	99.42	gold quality
mammalian vulva	UBERON:0000997	99.42	gold quality
cerebellar vermis	UBERON:0004720	99.41	gold quality
cardiac atrium	UBERON:0002081	99.40	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.40	gold quality
pituitary gland	UBERON:0000007	99.39	gold quality
cerebellar cortex	UBERON:0002129	99.37	gold quality
adenohypophysis	UBERON:0002196	99.37	gold quality
cerebellar hemisphere	UBERON:0002245	99.37	gold quality
adult organism	UBERON:0007023	99.36	gold quality
cerebellum	UBERON:0002037	99.35	gold quality
ventral tegmental area	UBERON:0002691	99.35	gold quality
middle temporal gyrus	UBERON:0002771	99.34	gold quality
cingulate cortex	UBERON:0003027	99.34	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	99.33	gold quality
anterior cingulate cortex	UBERON:0009835	99.33	gold quality
dorsal root ganglion	UBERON:0000044	99.31	gold quality
renal medulla	UBERON:0000362	99.31	gold quality
nucleus accumbens	UBERON:0001882	99.31	gold quality
endometrium epithelium	UBERON:0004811	99.31	gold quality
pigmented layer of retina	UBERON:0001782	99.30	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.30	gold quality
retina	UBERON:0000966	99.28	gold quality
seminal vesicle	UBERON:0000998	99.28	gold quality
body of tongue	UBERON:0011876	99.27	gold quality
heart	UBERON:0000948	99.26	gold quality
caudate nucleus	UBERON:0001873	99.26	gold quality
amygdala	UBERON:0001876	99.24	gold quality
putamen	UBERON:0001874	99.21	gold quality
parotid gland	UBERON:0001831	99.20	gold quality
medulla oblongata	UBERON:0001896	99.20	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.20	gold quality
mucosa of transverse colon	UBERON:0004991	99.20	gold quality
neocortex	UBERON:0001950	99.19	gold quality
ventricular zone	UBERON:0003053	99.19	gold quality
cerebral cortex	UBERON:0000956	99.17	gold quality
frontal cortex	UBERON:0001870	99.17	gold quality
frontal lobe	UBERON:0016525	99.17	gold quality
oral cavity	UBERON:0000167	99.13	gold quality
forebrain	UBERON:0001890	99.13	gold quality
telencephalon	UBERON:0001893	99.12	gold quality
frontal pole	UBERON:0002795	99.12	gold quality
upper leg skin	UBERON:0004262	99.12	gold quality
brain	UBERON:0000955	99.11	gold quality
gastrocnemius	UBERON:0001388	99.10	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.10	gold quality
central nervous system	UBERON:0001017	99.09	gold quality
vastus lateralis	UBERON:0001379	99.09	gold quality
inferior olivary complex	UBERON:0002127	99.09	gold quality
temporal lobe	UBERON:0001871	99.08	gold quality
cortical plate	UBERON:0005343	99.08	gold quality
pharyngeal mucosa	UBERON:0000355	99.07	gold quality
jejunal mucosa	UBERON:0000399	99.07	gold quality
hypothalamus	UBERON:0001898	99.07	gold quality
jejunum	UBERON:0002115	99.06	gold quality
upper arm skin	UBERON:0004263	99.06	gold quality
triceps brachii	UBERON:0001509	99.05	gold quality
dorsal plus ventral thalamus	UBERON:0001897	99.04	gold quality
bone marrow	UBERON:0002371	99.04	gold quality
adrenal tissue	UBERON:0018303	99.04	gold quality
Ammon’s horn	UBERON:0001954	99.02	gold quality
metanephros cortex	UBERON:0010533	99.02	gold quality
midbrain	UBERON:0001891	99.00	gold quality
nipple	UBERON:0002030	99.00	gold quality
duodenum	UBERON:0002114	99.00	gold quality
trigeminal ganglion	UBERON:0001675	98.99	gold quality
gluteal muscle	UBERON:0002000	98.99	gold quality
biceps brachii	UBERON:0001507	98.97	gold quality
substantia nigra	UBERON:0002038	98.96	gold quality
quadriceps femoris	UBERON:0001377	98.95	gold quality
tongue	UBERON:0001723	98.95	gold quality
myocardium	UBERON:0002349	98.95	gold quality
body of stomach	UBERON:0001161	98.94	gold quality
skin of abdomen	UBERON:0001416	98.94	gold quality
zone of skin	UBERON:0000014	98.92	gold quality
paraflocculus	UBERON:0005351	98.92	gold quality
adult mammalian kidney	UBERON:0000082	98.91	gold quality

Single-cell (SCXA)

Detected in 26 experiment(s), a significant marker in 17.

Experiment	Marker?	Max mean expression
E-MTAB-10042	yes	7131.29
E-MTAB-7407	yes	6350.25
E-GEOD-130473	yes	5140.73
E-CURD-112	yes	4116.43
E-HCAD-24	yes	3629.86
E-HCAD-4	yes	3590.30
E-CURD-122	yes	3522.79
E-MTAB-8205	yes	2106.04
E-CURD-6	yes	2088.35
E-GEOD-81383	yes	501.34
E-HCAD-6	yes	55.81
E-HCAD-10	yes	49.70
E-MTAB-9221	yes	16.15
E-HCAD-9	yes	9.72
E-MTAB-9067	yes	8.05

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 79 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Tongue	tissue	791.4
Skeletal muscle	tissue	677.5	high
Heart muscle	tissue	659.2	medium
Bone marrow	tissue	647.0	high
Superior colliculi	tissue	467.6
Thalamus	tissue	461.0
Pons	tissue	444.2
Postcentral gyrus	tissue	443.6
Spinal cord	tissue	436.6
Parathyroid gland	tissue	426.5	high
Locus coeruleus	tissue	401.1
Midbrain	tissue	389.5
Cerebral cortex	tissue	371.4	high
Somatosensory cortex	tissue	371.4
Medulla oblongata	tissue	370.0
Putamen	tissue	365.7
Adrenal gland	tissue	365.2	high
Basal ganglia	tissue	350.4	high
Occipital cortex	tissue	341.0
Frontal cortex	tissue	339.4
Motor cortex	tissue	335.1
Caudate putamen	tissue	326.3
Substantia nigra	tissue	323.4
Hippocampal formation	tissue	321.5
Choroid plexus	tissue	321.4
Pituitary gland	tissue	318.6
Ventral forebrain	tissue	318.2
Prefrontal cortex	tissue	302.5
Septum	tissue	302.2
Retrosplenial and cingulate cortex	tissue	299.8
Temporal cortex	tissue	293.2
Hippocampus	tissue	284.5	high
Entorhinal cortex	tissue	284.4
Cerebellum	tissue	283.5	high
Nucleus accumbens	tissue	277.4
Hypothalamus	tissue	275.0
Olfactory bulb	tissue	272.0
Retrosplenial cortex	tissue	270.7
Periaqueductal gray	tissue	263.9
Insular cortex	tissue	253.7
Amygdala	tissue	240.4
Duodenum	tissue	236.5	medium
Ovary	tissue	230.1	medium
Esophagus	tissue	219.5	medium
Liver	tissue	210.5	medium
Corpus callosum	tissue	207.4
Skin 1	tissue	200.3	medium
Retina	tissue	192.4
Small intestine	tissue	189.3	medium
Salivary gland	tissue	188.4	medium
Adipose tissue	tissue	186.7	medium
Kidney	tissue	185.1	high
Pancreas	tissue	183.7	high
Vagina	tissue	170.9	not detected
Thymus	tissue	168.8
Thyroid gland	tissue	140.7	high
Urinary bladder	tissue	138.8	high
Colon	tissue	137.3	medium
Epididymis	tissue	136.6	high
Fallopian tube	tissue	133.5	high

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Ventral spinal cord (436.6), Spinal trigeminal nucleus, interpolar (410.8), Cerebellar nuclei (409.8), Nuclei of the trapezoid body (405.1), Nucleus raphe magnus (401.0).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ARNT, EPAS1, HIF1A

miRNA regulators (miRDB)

Targeting PRDX2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

11 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-3922-3P	99.25	64.96	1136
HSA-MIR-3176	99.25	64.35	954
HSA-MIR-4443	98.02	66.25	1928
HSA-MIR-6515-5P	97.08	65.48	1219
HSA-MIR-7847-3P	96.63	64.58	952

Functional genomics

gnomAD constraint: pLI 0.0444, LOEUF 0.854, missense Z 1.02 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000301522 — one region, missense o/e 0.87.

Literature-anchored findings (GeneRIF, showing 40)

• Protein levels of Prx-I and Prx-II were significantly increased in Alzheimer Disease and Down Syndrome. (PMID:11771746)
• Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site (PMID:11904290)
• 2-Cys Prxs act in a mutually nonredundant and sometimes stress-specific fashion to protect human cells from oxidant injury. The substantial resistance of human cells to hydroperoxides may result in part from the additive action of multiple Prxs (PMID:12080185)
• Peroxiredoxin 2 levels are significantly increased in the frontal cortex of patients with Down syndrome, Alzheimer and Pick’s disease and provides evidence for existence of compensatory response in increased cell loss. (PMID:12650976)
• decreased expression of PRDX2 may contribute to the altered redox state in Down syndrome at levels comparable to that of the increased expression of SOD1 (PMID:12943237)
• Prx II can be used as a novel marker of vascular tumors and preferential expression of Prx II is found in benign vascular tumors. (PMID:12963914)
• results show that sestrins, a family of proteins whose expression is modulated by p53, are required for regeneration of peroxiredoxins containing Cys-SO(2)H (PMID:15105503)
• Prx I and Prx II are induced at the early and late stage of differentiation of normal human epidermal keratinocytes. (PMID:15864612)
• loss of IDPc and Prx-II during tumor development may involve in tumor progression and metastasis (PMID:15936593)
• PDX2 was involved in malignant transformation of human bronchial epithelial cell induced by crystalline nickel sulfide. (PMID:16188094)
• in the erythrocyte Prx2 is extremely efficient at scavenging H(2)O(2) noncatalytically (PMID:17105810)
• We propose a model in which Prxs function as peroxide dosimeters in subcellular processes that involve redox cycling, with hyperoxidation controlling structural transitions that alert cells of perturbations in peroxide homeostasis. (PMID:17145963)
• peroxiredoxin 2 has a tertiary structure that facilitates reaction of the active site thiol with hydrogen peroxide while restricting its reactivity with other thiol reagents (PMID:17329258)
• Human Prdx1 and Prdx2 possess unique functions and regulatory mechanisms and that Cys(83) bestows a distinctive identity to Prdx1. (PMID:17519234)
• PrxII might play an important role in hepatocarcinogenesis and might be used as a molecular target for HCC prevention and treatment. (PMID:17524271)
• observation of increased SNO-Prx2 in human Parkinson’s disease (PD) brains, and S-nitrosylation of Prx2 inhibited both its enzymatic activity and protective function from oxidative stress (PMID:18003920)
• Peroxiredoxin II (PRXII) exclusively expressed in bronchiolitis obliterans syndrome. (PMID:18022079)
• Significantly decreased expression of Prx-2, -3, and -5 in FED may suggest an alteration in the ability of endothelial cells to withstand oxidant-induced damage and may be closely related to the pathogenesis of this disease. (PMID:18378575)
• study reports identification of Prx2 in the erythrocyte membrane from hereditary spherocytosis patients; presence of Prx2 in erythrocyte membranes was linked to higher levels of oxidative stress, as reflected by increased membrane bound hemoglobin (PMID:18387321)
• 2-cysteine peroxiredoxins from Homo sapiens, Arabidopsis thaliana, and Pisum sativum as well as a carboxy-terminally truncated variant were subjected to isothermal titration calorimetry analysis. (PMID:18553980)
• Silencing of PRDX2 caused decreased rates of Hep3B cell growth and clone formation, increased rates of cell apoptosis, and increased the levels of endogenous ROS and MDA. (PMID:18578994)
• analysis of a protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin (PMID:18593714)
• The results suggest that Prx II oxidation does not relate to the pathogenesis of IPF/UIP (PMID:18606608)
• peroxiredoxin (Prx) I and Prx II are specific targets of HDAC6 (PMID:18606987)
• inhibiting peroxiredoxin II sensitizes glioma cells to oxidative stress (PMID:18718523)
• Prx2 is a key antioxidant enzyme for the erythrocyte and reveal red blood cells as active oxidant scrubbers in the bloodstream. (PMID:19061854)
• These results indicate that both nipradilol and timolol possess a novel mechanism of action and function as potent protective agents against oxidative stress. (PMID:19151395)
• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• Prx II is more susceptible than Prx I to hyperoxidation and that the majority of the hyperoxidized Prx II formation is reversible. However, the hyperoxidized Prx I showed much less reversibility (PMID:19286652)
• Conclude that Prx II and III are upregulated in response to the development of cervical cancer. (PMID:19424615)
• Deglutathionylation of 2-Cys Prx is specifically catalyzed by Srx. (PMID:19561357)
• Resutls show that three of five autoantibodies, FKBP52, PPIA, and PRDX2, showed significantly increased reactivity in primary breast cancer and CIS compared with healthy controls. (PMID:19584157)
• P. falciparum imports the human redox-active protein peroxiredoxin 2 (hPrx-2, hTPx1) into its cytosol. (PMID:19666612)
• Exposure to Chloramines and hypochlorous acid inflammatory oxidants will result in Prx2 oxidation and could compromise the erythrocyte’s ability to resist damaging oxidative insult. (PMID:19716412)
• could act as an autoantigen of a streptococcal-induced autoimmune response and represents a target of the exaggerated T cell response in psoriasis. (PMID:20363977)
• Data suggest that anti-Prx2 autoantibodies would be a useful marker for systemic vasculitis and would be involved in the inflammatory processes of systemic vasculitis. (PMID:20646000)
• PRDX2 was up-regulated in women older than 38 years, and its expression in cumulus cells was associated with embryo quality (PMID:20721618)
• Addition of an uncharged derivative of leucine hydroperoxide to intact erythrocytes caused Prx2 oxidation with no concomitant loss in glutathione. (PMID:20840079)
• proteomic profiling used to identify the target proteins of miR-122a in hepatocellular carcinoma; PRDXII was identified to be the new target of miR-122a (PMID:20859956)
• High PRDX2 expression in the cytoplasm is associated with uterine cervix carcinogenesis. (PMID:21119665)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Prdx2	ENSMUSG00000005161
rattus_norvegicus	Prdx2	ENSRNOG00000003520
drosophila_melanogaster	Prx6c	FBGN0033518
drosophila_melanogaster	Prx6b	FBGN0033520
drosophila_melanogaster	CG12896	FBGN0033521

Paralogs (4): PRDX1 (ENSG00000117450), PRDX6 (ENSG00000117592), PRDX4 (ENSG00000123131), PRDX3 (ENSG00000165672)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:109486) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 18 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased hematocrit	1
abnormal erythropoiesis	1
echinocytosis	1
schistocytosis	1
enlarged spleen	1
hemolytic anemia	1
abnormal bone marrow cell morphology/development	1
abnormal proerythroblast morphology	1
abnormal erythrocyte morphology	1
reticulocytosis	1
spherocytosis	1
decreased hemoglobin content	1
increased spleen weight	1
hemosiderosis	1
increased cellular sensitivity to hydrogen peroxide induced cell death	1
increased cellular sensitivity to oxidative stress	1
increased spleen red pulp amount	1
increased number of Heinz bodies	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Staphylococcus aureus subsp. aureus Mu50	P0A0B5	100.0%	Diamond
Staphylococcus aureus subsp. aureus MW2	P0A0B6	100.0%	Diamond
Staphylococcus aureus subsp. aureus NCTC 8325	P0A0B7	100.0%	Diamond
Salmonella enterica subsp. enterica serovar Typhimurium str. LT2	P0A251	100.0%	Diamond
Salmonella enterica subsp. enterica serovar Typhi	P0A252	100.0%	Diamond
Escherichia coli K-12	P0AE08	100.0%	Diamond
Escherichia coli CFT073	P0AE09	100.0%	Diamond
Escherichia coli O157:H7	P0AE10	100.0%	Diamond
Shigella flexneri	P0AE11	100.0%	Diamond
Candida albicans SC5314	P0CU34	100.0%	Diamond
Mycobacterium tuberculosis variant bovis AF2122/97	P65689	100.0%	Diamond
Staphylococcus aureus subsp. aureus N315	P99074	100.0%	Diamond
Mycobacterium tuberculosis CDC1551	P9WIE0	100.0%	Diamond
Mycobacterium tuberculosis H37Rv	P9WIE1	100.0%	Diamond
Staphylococcus aureus subsp. aureus USA300	Q2FJN4	100.0%	Diamond
Macaca fascicularis	Q2PFZ3	100.0%	Diamond
Staphylococcus aureus RF122	Q2YVK2	100.0%	Diamond
Staphylococcus aureus subsp. aureus COL	Q5HIR5	100.0%	Diamond
Staphylococcus aureus subsp. aureus MSSA476	Q6GC91	100.0%	Diamond
Staphylococcus aureus subsp. aureus MRSA252	Q6GJR7	100.0%	Diamond
Triticum aestivum	P80602	99.5%	Diamond
Staphylococcus epidermidis RP62A	Q5HRY1	99.5%	Diamond
Staphylococcus epidermidis ATCC 12228	Q8CMQ2	99.5%	Diamond
Hordeum vulgare	Q96468	99.5%	Diamond
Pongo abelii	Q5RC63	99.4%	Diamond
Myotis lucifugus	Q6B4U9	99.0%	Diamond
Spinacia oleracea	O24364	98.5%	Diamond
Helicobacter pylori 26695	P21762	98.5%	Diamond
Helicobacter pylori J99	P56876	98.5%	Diamond
Arabidopsis thaliana	Q96291	98.5%	Diamond
Bromus secalinus	P52571	97.5%	Diamond
Bos taurus	O77834	97.3%	Diamond
Sus scrofa	Q9TSX9	97.3%	Diamond
Methanococcus maripaludis C5	A4FWZ9	97.2%	Diamond
Thermotoga petrophila RKU-1	A5IIX7	97.2%	Diamond
Methanococcus maripaludis S2	Q6LY19	97.2%	Diamond
Thermotoga maritima MSB8	Q9WZR4	97.2%	Diamond
Cricetulus griseus	Q8K3U7	96.5%	Diamond
Methanothermobacter thermautotrophicus str. Delta H	O26262	95.7%	Diamond
Methanothermobacter marburgensis str. Marburg	Q57109	95.7%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
HOOK2	protein-coding	29911
JUNB	protein-coding	3726
GET3	protein-coding	439
BEST2	protein-coding	54831
MIR6794	ncRNA	102466196
RTBDN-AS1	ncRNA	105372281
THSD8	protein-coding	111644133
MAST1	protein-coding	22983
RTBDN	protein-coding	83546
RNASEH2A	protein-coding	10535
MIR5684	ncRNA	100847071

Protein

Protein identifiers

Peroxiredoxin-2 — P32119 (reviewed: P32119)

Alternative names: Natural killer cell-enhancing factor B, PRP, Thiol-specific antioxidant protein, Thioredoxin peroxidase 1, Thioredoxin-dependent peroxide reductase 1, Thioredoxin-dependent peroxiredoxin 2

All UniProt accessions (3): P32119, A6NIW5, V9HW12

UniProt curated annotations — full annotation on UniProt →

Function. Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2).

Subunit / interactions. Homodimer; disulfide-linked, upon oxidation. 5 homodimers assemble to form a ring-like decamer. Interacts with TIPIN.

Subcellular location. Cytoplasm.

Post-translational modifications. The enzyme can be inactivated by further oxidation of the cysteine sulfenic acid (C(P)-SOH) to sulphinic acid (C(P)-SO2H) instead of its condensation to a disulfide bond. It can be reactivated by forming a transient disulfide bond with sulfiredoxin SRXN1, which reduces the cysteine sulfinic acid in an ATP- and Mg-dependent manner. Acetylation increases resistance to transition to high molecular-mass complexes. Deacetylated by HDAC6 which decreases reducing activity.

Miscellaneous. The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this typical 2-Cys peroxiredoxin, C(R) is provided by the other dimeric subunit to form an intersubunit disulfide. The disulfide is subsequently reduced by thioredoxin. Due to intron retention. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the peroxiredoxin family. AhpC/Prx1 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P32119-1	1	yes
P32119-2	2

RefSeq proteins (1): NP_005800* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000866	AhpC/TSA	Domain
IPR013766	Thioredoxin_domain	Domain
IPR019479	Peroxiredoxin_C	Domain
IPR024706	Peroxiredoxin_AhpC-typ	Family
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR050217	Peroxiredoxin	Family

Pfam: PF00578, PF10417

Enzyme classification (BRENDA)

• EC 1.11.1.24 — thioredoxin-dependent peroxiredoxin (BRENDA: 72 organisms, 110 substrates, 31 inhibitors, 72 Km, 50 kcat entries)

Substrate kinetics (BRENDA)

13 substrates with measured Km, best-characterized 13. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
H2O2	0.0004–11.7	23
CUMENE HYDROPEROXIDE	0.0066–0.191	8
THIOREDOXIN	0.001–0.0794	7
TERT-BUTYL HYDROPEROXIDE	—	5
THIOREDOXIN A	0.0009–0.0122	5
THIOREDOXIN B	0.0022–0.0208	5
T-BUTYL HYDROPEROXIDE	0.072–0.193	4
THIOREDOXIN Q	0.0007–0.0028	4
REDUCED THIOREDOXIN	0.0024–0.004	2
REDUCED THIOREDOXIN A	0.0079–0.0087	2
ETHYL HYDROPEROXIDE	0.0045	1
LINOLEIC ACID HYDROPEROXIDE	0.117	1
TRYPAREDOXIN 2	0.0319	1

Catalyzed reactions (Rhea)

• a hydroperoxide + [thioredoxin]-dithiol = an alcohol + [thioredoxin]-disulfide + H2O (RHEA:62620)

UniProt features (38 total): helix 9, sequence conflict 7, strand 7, modified residue 4, turn 2, disulfide bond 2, initiator methionine 1, chain 1, splice variant 1, sequence variant 1, mutagenesis site 1, domain 1, active site 1

Structure

Experimental structures (PDB)

7 structures by resolution:

PDB	Title	Method	Resolution (Å)
1QMV	thioredoxin peroxidase B from red blood cells	X-RAY DIFFRACTION	1.7
7KIZ	reduced human peroxiredoxin 2	X-RAY DIFFRACTION	1.7
5IJT	Human Peroxiredoxin 2 Oxidized (SS)	X-RAY DIFFRACTION	2.15
7KJ1	human peroxiredoxin 2 - C172S mutant	X-RAY DIFFRACTION	2.15
7KJ0	hyperoxidized human peroxiredoxin 2	X-RAY DIFFRACTION	2.29
5B8A	Crystal structure of oxidized chimeric EcAhpC1-186-YFSKHN	X-RAY DIFFRACTION	2.7
5B8B	Crystal structure of reduced chimeric E.coli AhpC1-186-YFSKHN	X-RAY DIFFRACTION	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P32119-F1	97.87	0.99

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Oxidoreductases, Metabolic proteins, Predicted intracellular proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers, Essential proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol

Antibody reliability (HPA): IH supported · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
51	cysteine sulfenic acid (-soh) intermediate

Post-translational modifications (4)

Type	Positions
N-acetylalanine	2
Phosphoserine	112
Phosphothreonine	182
N6-acetyllysine	196

Disulfide bonds (2)

Type	Positions
Interchain (with c-172)	51
Interchain (with c-51)	172

Mutagenesis-validated functional residues (1)

Position	Phenotype
196	abolishes acetylation.

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 14; 5 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

14 pathways:

ID	Pathway	Evidence
R-HSA-3299685	Detoxification of Reactive Oxygen Species	curated
R-HSA-5628897	TP53 Regulates Metabolic Genes	curated
R-HSA-9734009	Defective Intrinsic Pathway for Apoptosis ⚕	—
R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models ⚕	electronic
R-HSA-1643685	Disease ⚕	—
R-HSA-9645723	Diseases of programmed cell death ⚕	—
R-HSA-8863678	Neurodegenerative Diseases ⚕	—
R-HSA-9711123	Cellular response to chemical stress	—
R-HSA-8953897	Cellular responses to stimuli	—
R-HSA-2262752	Cellular responses to stress	—
R-HSA-74160	Gene expression (Transcription)	—
R-HSA-212436	Generic Transcription Pathway	—
R-HSA-73857	RNA Polymerase II Transcription	—
R-HSA-3700989	Transcriptional Regulation by TP53	—

MSigDB gene sets: 361 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GNF2_PRDX2, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_INFLAMMATORY_RESPONSE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_REGULATION_OF_COAGULATION, JAEGER_METASTASIS_DN, CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_HYDROGEN_PEROXIDE_CATABOLIC_PROCESS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_POSITIVE_REGULATION_OF_COAGULATION, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE

GO Biological Process (11): defense response to tumor cell (GO:0002357), response to oxidative stress (GO:0006979), removal of superoxide radicals (GO:0019430), positive regulation of blood coagulation (GO:0030194), cellular response to oxidative stress (GO:0034599), hydrogen peroxide catabolic process (GO:0042744), regulation of apoptotic process (GO:0042981), negative regulation of apoptotic process (GO:0043066), leukocyte activation (GO:0045321), cell redox homeostasis (GO:0045454), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (7): thioredoxin peroxidase activity (GO:0008379), antioxidant activity (GO:0016209), peroxidase activity (GO:0004601), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), peroxiredoxin activity (GO:0051920), thioredoxin-dependent peroxiredoxin activity (GO:0140824)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), extracellular exosome (GO:0070062)

Reactome top-level categories

11 top-level categories:

Category	Pathways
Cellular response to chemical stress	1
Transcriptional Regulation by TP53	1
Neurodegenerative Diseases	1
RNA Polymerase II Transcription	1
Cellular responses to stimuli	1
Generic Transcription Pathway	1
Gene expression (Transcription)	1
Defective Intrinsic Pathway for Apoptosis	1
Disease	1
Cellular responses to stress	1
Diseases of programmed cell death	1

GO top-level categories

35 GO namespaces:

Category	Terms
cellular oxidant detoxification	2
apoptotic process	2
cellular anatomical structure	2
response to tumor cell	1
defense response	1
response to stress	1
superoxide metabolic process	1
cellular response to superoxide	1
blood coagulation	1
regulation of blood coagulation	1
positive regulation of coagulation	1
positive regulation of wound healing	1
positive regulation of hemostasis	1
response to oxidative stress	1
cellular response to chemical stress	1
catabolic process	1
hydrogen peroxide metabolic process	1
regulation of programmed cell death	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
cell activation	1
immune system process	1
cellular homeostasis	1
cellular detoxification	1
thioredoxin-dependent peroxiredoxin activity	1
molecular_function	1
antioxidant activity	1
oxidoreductase activity, acting on peroxide as acceptor	1
binding	1
catalytic activity	1
peroxidase activity	1
peroxiredoxin activity	1
intracellular anatomical structure	1
cytoplasm	1
extracellular vesicle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 9 of 21 annotations. The rest are phylogenetic / computational / electronic (IEA).

9 experimentally-supported GO terms:

GO term	NS	Evidence
cellular response to oxidative stress	BP	direct assay
defense response to tumor cell	BP	mutant phenotype
regulation of apoptotic process	BP	mutant phenotype
removal of superoxide radicals	BP	direct assay
response to oxidative stress	BP	mutant phenotype
cytosol	CC	direct assay
extracellular exosome	CC	high-throughput assay
antioxidant activity	MF	direct assay
thioredoxin peroxidase activity	MF	direct assay

Protein interactions and networks

IntAct

Human interaction partners of PRDX2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

26 partners by confidence:

Partner	Interaction type	MIscore	Records
TXN	association	0.560	2
PRDX3	association	0.510	2
STAT3	physical association	0.500	3
BAD	physical association	0.440	2
DNMT3A	physical association	0.400	1
A2M	physical association	0.370	1
CA4	physical association	0.370	1
CD320	physical association	0.370	1
CDC37	physical association	0.370	1
COPS5	physical association	0.370	1
ECSIT	physical association	0.370	1
EXOC6	physical association	0.370	1
IFIT5	physical association	0.370	1
MAST1	physical association	0.370	1
NLGN3	physical association	0.370	1
PRDX4	physical association	0.370	1
RNF32	physical association	0.370	1
SAT1	physical association	0.370	1
UTY	physical association	0.370	1
YWHAZ	physical association	0.370	1
FAM171A2	association	0.350	1
TXNDC9	association	0.350	1
COL14A1	physical association	0.000	1
KCTD5	physical association	0.000	1
MAK	physical association	0.000	1
RTL9	physical association	0.000	1

BioGRID (408 interactions; top human partners by supporting records): PRDX1 (Co-fractionation; 21 records), RPL4 (Affinity Capture-MS; 4 records), TXNDC5 (Affinity Capture-MS; 4 records), DPYSL2 (Affinity Capture-MS; 3 records), MYC (Affinity Capture-MS; 3 records), PARK2 (Affinity Capture-MS; 3 records), PRDX5 (Co-fractionation; 3 records), PRDX6 (Co-fractionation; 3 records), SOD1 (Co-fractionation; 3 records), AGR2 (Proximity Label-MS; 2 records), APP (Affinity Capture-MS; 2 records), CCT2 (Affinity Capture-MS; 2 records), CDK1 (Co-fractionation; 2 records), CDK2 (Affinity Capture-Western; 2 records), CFTR (Affinity Capture-MS; 2 records)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
LCK	“down-regulates activity”	PRDX2	phosphorylation
ABL1	“down-regulates activity”	PRDX2	phosphorylation

Disease & clinical

Genetic variants

Variant evidence for PRDX2: 20 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	12
Likely benign	0
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 28 predictions of 460):

Position(s)	Effect	Δscore	Sites
19:12799857–12799858	donor_loss	1.0000	5
19:12800175–12800176	donor_loss	1.0000	4
19:12800195	donor_gain	1.0000
19:12800300–12800301	acceptor_loss	1.0000	5
19:12800914	donor_loss	1.0000
19:12801070–12801071	acceptor_loss	1.0000	6
19:12801157–12801158	donor_loss	1.0000	3
19:12799861	donor_gain	0.9900
19:12800176	donor_loss	0.9900
19:12800300	acceptor_loss	0.9900

AlphaMissense

684 missense substitutions predicted likely pathogenic (of 1,292 scored), across 156 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D78	8	0.992	0.997
H83	8	0.984	0.997
D106	8	0.979	0.993
D46	8	0.977	0.996
F49	8	0.972	0.999
F47	8	0.967	0.999
D145	8	0.958	0.983
F194	8	0.952	0.991
F65	8	0.944	0.995
D133	8	0.943	0.990
F58	8	0.919	0.988
F42	8	0.911	0.992
F15	8	0.882	0.981
F25	8	0.877	0.973
E54	7	0.993	0.998
W86	7	0.992	0.998
R127	7	0.992	1.000
W176	7	0.991	0.998
C51	7	0.987	0.998
F81	7	0.985	0.998

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

5 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	7.87e-07
Kidney Renal Papillary Cell Carcinoma (TCGA)	favorable	1.13e-06
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	favorable	0.000423
Lung Squamous Cell Carcinoma (TCGA)	favorable	0.000605
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000645

Disease associations

OMIM: gene MIM:600538 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST90002401_233	Platelet distribution width	3e-21

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295744 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

2 measured of 2 human assays (4 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5565154	IC50	350 nM
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.16	Kd	6924	nM	CHEMBL5653589
5.16	ED50	6924	nM	CHEMBL5653589
5.10	Kd	7995	nM	CHEMBL3752910
5.10	ED50	7995	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 27 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149062: Binding affinity to human PRDX2 incubated for 45 mins by Kinobead based pull down assay	kd	6.9239	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149062: Binding affinity to human PRDX2 incubated for 45 mins by Kinobead based pull down assay	kd	7.9953	uM

CTD chemical–gene interactions

101 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, decreases methylation, increases expression	4
sodium arsenite	increases expression	4
Hydrogen Peroxide	increases expression, increases oxidation, decreases response to substance	4
Valproic Acid	affects expression, decreases expression, increases methylation	4
Cisplatin	increases expression, affects response to substance, decreases response to substance	3
bisphenol F	increases expression, affects cotreatment, decreases expression	2
ochratoxin A	increases acetylation, increases expression	2
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression, decreases expression	2
Aerosols	decreases expression	2
Benzo(a)pyrene	decreases expression, increases expression, decreases reaction	2
Cocaine	affects expression, decreases expression	2
Doxorubicin	affects expression, decreases response to substance	2
Estradiol	decreases expression	2
Formaldehyde	increases expression, decreases expression, decreases reaction, increases activity	2
Lead	affects expression, decreases expression	2
Paraquat	increases expression, affects cotreatment	2
Quercetin	affects cotreatment, increases expression, decreases expression, decreases reaction	2
Tobacco Smoke Pollution	affects expression	2
Cyclosporine	decreases expression	2
tert-Butylhydroperoxide	decreases expression, increases expression	2
Nanotubes, Carbon	affects expression, increases expression	2
Particulate Matter	increases expression, increases response to substance, decreases expression	2
dicrotophos	increases expression	1
uranyl acetate	affects expression	1
cumene hydroperoxide	increases expression	1
deoxynivalenol	decreases expression	1
lead acetate	affects cotreatment, increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression	1
4-vinyl-1-cyclohexene dioxide	increases expression	1
arsenite	affects binding, increases reaction	1

ChEMBL screening assays

20 unique, capped per target: 20 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4144685	Binding	Binding affinity to wild type recombinant human N-terminal 6His-tagged peroxiredoxin-2 expressed in Escherichia coli BL21 after 1 hr by LC-MS/MS analysis	ent-Jungermannenone C Triggers Reactive Oxygen Species-Dependent Cell Differentiation in Leukemia Cells. — *J Nat Prod*

Cellosaurus cell lines

6 cell lines: 5 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3ES	Abcam HEK293T PRDX2 KO	Transformed cell line	Female
CVCL_KT96	HeLa SilenciX PRDX2	Cancer cell line	Female
CVCL_TG44	HAP1 PRDX2 (-) 1	Cancer cell line	Male
CVCL_TG45	HAP1 PRDX2 (-) 2	Cancer cell line	Male
CVCL_TG46	HAP1 PRDX2 (-) 3	Cancer cell line	Male
CVCL_TG47	HAP1 PRDX2 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PRDX2 across ~30M SureChEMBL compounds — explore on Sugi Predict.